CN107519163A - 大花红景天素的医药用途 - Google Patents
大花红景天素的医药用途 Download PDFInfo
- Publication number
- CN107519163A CN107519163A CN201610458230.1A CN201610458230A CN107519163A CN 107519163 A CN107519163 A CN 107519163A CN 201610458230 A CN201610458230 A CN 201610458230A CN 107519163 A CN107519163 A CN 107519163A
- Authority
- CN
- China
- Prior art keywords
- rhodiola
- tyrosinase
- present
- dopa
- melanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001165494 Rhodiola Species 0.000 title claims abstract description 35
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 25
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 32
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 6
- -1 flavone compound Chemical class 0.000 description 6
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 6
- 229960004705 kojic acid Drugs 0.000 description 6
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 6
- 229960004502 levodopa Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- PGNRLPTYNKQQDY-UHFFFAOYSA-N 2,3-dihydroxyindole Chemical compound C1=CC=C2C(O)=C(O)NC2=C1 PGNRLPTYNKQQDY-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- POVCYOFRCMBMKD-XMSQKQJNSA-N (2r,3r)-6,8-dihydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-9-(4-hydroxyphenyl)-2,3-dihydropyrano[3,2-h][1,4]benzodioxin-7-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=C4C(C(C(O)=C(O4)C=4C=CC(O)=CC=4)=O)=C(O)C=C3O2)CO)=C1 POVCYOFRCMBMKD-XMSQKQJNSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 101800000241 Allatostatin-4 Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- POVCYOFRCMBMKD-UHFFFAOYSA-N rhodiolinin Natural products C1=C(O)C(OC)=CC(C2C(OC3=C4C(C(C(O)=C(O4)C=4C=CC(O)=CC=4)=O)=C(O)C=C3O2)CO)=C1 POVCYOFRCMBMKD-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及医药领域，特别是涉及一种大花红景天素的医药用途。本发明的大花红景天素可用于制备抑制酪氨酸酶活性的药物、保健品和化妆品。
Description
技术领域
本发明涉及医药保健品领域，特别是涉及一种黄酮类化合物的用途及其相关产品。
背景技术
色素沉着是由于黑色素过度积累导致的。临床主要表现为雀斑、褐斑甚至黑色素瘤等皮肤问题和疾病。
目前一般认为黑色素合成途径是：酪氨酸在酪氨酸酶作用下生成多巴，多巴在酪氨酸酶作用下生成多巴醌，多巴醌形成多巴色素，多巴色素形成二羟基吲哚，二羟基吲哚氧化成酮式吲哚，最后酮式吲哚聚合成真黑素。在这条反应途径中，多巴醌还可以经谷胱甘肽酶或半胱氨酸酶催化生成褐黑素，真黑素与褐黑素组成了黑色素，其中真黑素是皮肤色素的主要组成部分，褐黑素在皮肤中的功效暂不清楚。
目前治疗色素沉着的西药主要为氢醌及其衍生物化合物。其安全窗较小，长期使用会在体内大量积蓄，引起皮肤毒性、致癌性、遗传毒性等毒副作用。曲酸和熊果酸等多酚类化合物的使用量也有非常严格的要求，过大剂量也会引起致癌，致畸等毒副作用。
大花红景天素(rhodiolinin)是一种黄酮类化合物，存在于多种植物中，具有抗氧化，抗病毒的作用。
发明内容
本发明的目的旨在提供一种大花红景天素的新用途。
具体地说，本发明的第一方面是提供了大花红景天素在制备抑制酪氨酸酶活性的药物或保健品或化妆品中的应用。
在一优选例中，所述的大花红景天素是作为唯一的活性成分应用于抑制酪氨酸酶活性的药物或保健品或化妆品的制备中。
本发明各个方面的细节将在随后的章节中得以详尽描述。通过下文以及权利要求的描述，本发明的特点、目的和优势将更为明显。
附图说明
图1为大花红景天素在薄层板上抑制黑色素生成形成的白色斑点的作用效果图；
图2为用B16黑色素瘤细胞模型筛选法检测大花红景天素抑制酪氨酸酶生成黑色素的能力；
图3为用以多巴为底物的分光光度法检测大花红景天素抑制酪氨酸酶生成黑色素的能力。
具体实施方式
本发明的问世是基于这样一个意外发现：黄酮类化合物大花红景天素在体内/体外均具有良好的抑制酪氨酸酶活性的作用。因此，大花红景天素有望开发成为一种抑制酪氨酸酶活性的药物或保健品或化妆品。
如本发明所用，本发明的化合物大花红景天素，其分子式：C25H20O10，分子量：480.11，其结构式如下：
如本领域的普通技术人员所知，本发明的化合物大花红景天素可通过商业途径购买获得，亦可用本领域的常规方法从景天科植物大花红景天(学名：Rhodiola crenulata(HK.f.et.Thoms)H.Ohba)等中提取获得。其纯度均符合药用标准。
本发明的大花红景天素可以单独使用或以药物组合物的形式使用。药物组合物包括作为活性成分的本发明的大花红景天素及可药用载体。较佳地，本发明的药物组合物含有0.1～99.9％重量百分比的作为活性成分的本发明的大花红景天素。“可药用载体”不会破坏本发明的大花红景天素的药学活性，同时其有效用量，即能发挥药物载体作用时的用量对人体无毒。
所述可药用载体包括但不限于：软磷脂、硬脂酸铝、氧化铝、离子交换材料、自乳化药物传递系统、吐温或其他表面活化剂、血清蛋白、缓冲物质如磷酸盐、氨基乙酸、山梨酸、水、盐、电解质如硫酸盐精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐、硅酸镁、饱和脂肪酸部分甘油酯混合物等。
其他常用的药物辅料如粘合剂(如微晶纤维素)、填充剂(如淀粉、葡萄糖、无水乳糖和乳糖珠粒)、崩解剂(如交联PVP、交联羧甲基淀粉钠、交联羧甲基纤维素钠、低取代羟丙基纤维素)、润滑剂(如硬脂酸镁)以及吸收促进剂、吸附载体、香味剂、甜味剂、赋形剂、稀释剂、润湿剂等。
本发明的大花红景天素以及其药物组合物可按本领域常规方法制备并可以通过肠道或非肠道或局部途径给药。口服制剂包括胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂等；非肠道给药制剂包括注射液等；局部给药制剂包括霜剂、贴剂、软膏剂、喷雾剂等。优选为口服制剂。
本发明的大花红景天素以及其药物组合物的给药途径可以为口服、舌下、经皮、经肌肉或皮下、皮肤粘膜、静脉、尿道、阴道等。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。除非另外说明，否则所有的百分数、比率、比例、或份数按重量计。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
本发明提到的上述特征，或实施例提到的特征可以任意组合。本专利说明书所揭示的所有特征可与任何组合物形式并用，说明书中所揭示的各个特征，可以任何可提供相同、均等或相似目的的替代性特征取代。因此除有特别说明，所揭示的特征仅为均等或相似特征的一般性例子。
实施例子1检测大花红景天素在薄层板上抑制抑制酪氨酸酶生成黑色素的能力
1.实验材料
1.1仪器与试药
硅胶铝板薄层预制板(Merck-F254，10cm×20cm，Düren，Germany)。恒温水浴锅(SC-15，上海比朗仪器有限公司，上海)；AST4薄层色谱仪系统(薄层色谱自动点样仪，薄层色谱数码成像仪，薄层色谱板加热器，薄层色谱扫描仪，薄层色谱自动侵入衍生化装置)购自CAMAG公司，瑞士。大花红景天素购自上海中药标准化研究中心，并经HPLC检测纯度均在98％以上。酪氨酸酶(T3824-50KU，SLBG4386V)，L-DOPA(100g，V900425)，曲酸(5g，K3125)均购自SIGMA公司，美国。
1.2样品溶液配制
取大花红景天素和曲酸适量，分别称定，加甲醇溶解配制成10mM的储备液，根据实验需要分别稀释成浓度范围为1～10mM的不同浓度的稀释液，0～4℃低温保存。
2.实验方法
将2μL供试品溶液点于Merck F254铝底硅胶预制薄层板上，挥干溶剂后，采用浸渍法，应用薄层色谱自动浸入衍生化装置将供试品板浸入酪氨酸酶溶液中1s，取出，拭去多余溶剂；再将该薄层板浸入底物L-DOPA溶液中1s，取出后置于25℃的密闭恒温水槽中反应15min，具有抑制酪氨酸酶活性的样品在薄层板的黑色背景下表现为白色斑点，以荧光模式，580nm为检测波长，对白色斑点进行扫描。实验结果见图1和表1。
表1大花红景天素在薄层板上抑制黑色素生成形成的白色斑点扫描数据表
实施例子2用B16黑色素瘤细胞模型筛选法检测大花红景天素抑制酪氨酸酶生成黑色素的能力
1实验材料
1.1仪器与试药
倒置荧光显微镜(CKX41，OLYMPUS，日本)，CO2恒温细胞培养箱(BB150，THERMO，美国)，超净工作台(1388，THERMO，美国)。恒温水浴锅(SC-15，上海比朗仪器有限公司，上海)；酶标仪(BOX-998，Winooski，美国)。酪氨酸酶(T3824-50KU，SLBG4386V)，L-DOPA(100g，V900425)，Vc(100g，A7506)，曲酸(5g，K3125)均购自SIGMA公司，美国。B16小鼠黑色素瘤细胞，由上海科学院细胞库提供。大花红景天素购自上海中药标准化研究中心，并经HPLC检测纯度均在98％以上。DMEM培养基(500mL，1638605)，0.25％Trypsin-EDTA(500mL，1584897)，澳洲胎牛血清(500mL，20012-027)，FBS(500mL，10099-141)，RPMI1640培养基(500mL，11875-093)，Penicillin-Streptomycin，Liquid(100mL，15140-122)均购自THERMO FISHER SCIENTIFIC公司，美国；Theophylline(P08250，DAMAS-BETA，中国)。
1.2样品溶液配制
取大花红景天素和曲酸适量，分别称定，加DMSO溶解配制成100mM的储备液，根据实验需要分别稀释成浓度范围为1～100mM的不同浓度的稀释液，0～4℃低温保存。
2.B16小鼠黑色素瘤细胞的培养
B16小鼠黑色素瘤细胞生长在含10％的胎牛血清、100U/mL青霉素、100U/mL链霉素的完全RPMI 1640培养基中。在37℃，5％CO2条件下培养下，细胞贴壁培养到对数期后，0.25％胰蛋白酶消化，以每瓶约106个细胞传代至100cm2的培养皿中，每3天传代一次。
3.B16小鼠黑色素瘤细胞增殖活性测定(CCK-8法)
取对数生长期细胞常规消化，用完全RPMI1640培养基调整细胞为5×104的细胞悬液，将细胞接种于96孔细胞培养板中，每孔199μL。在37℃，5％CO2条件下培养，加入1μL待测样品作用3天后，弃上清并用PBS洗涤两编，每孔添加100μL含10％CCK-8的培养基溶液后，在培养箱中反应1h，于酶标仪上450nm波长下测定吸光度。
4.B16小鼠黑色素瘤细胞酪氨酸酶活性实验
常规消化下的细胞用含1％茶碱的DMEM完全培养液将小鼠B16黑色素瘤细胞的密度调为5×104个/mL，每孔199μL接种于96孔细胞培养板中，加入1μL待测样品作用3天后，弃上清并用PBS洗涤两编，每孔添加80μL含1％TritonX-100的PBS溶液后，冰水浴中超声30s破碎，每孔加入4mM L-DOPA 50μL，37℃水浴孵育60min，分别取100μL移至96孔细胞培养板中，于酶标仪检测475nm波长下的吸光度值，计算细胞内酪氨酸酶活性抑制率[2]。实验结果见图2和表2(以下检测浓度都控制在没有细胞毒性范围内)。
酪氨酸酶抑制率计算使用以下公式：
表2用B16黑色素瘤细胞模型筛选法检测大花红景天素抑制酪氨酸酶生成黑色素的抑制率
实施例子3用以多巴为底物的分光光度法检测大花红景天素抑制酪氨酸酶生成黑色素的能力
1.实验材料
1.1仪器与试药
恒温水浴锅(SC-15，上海比朗仪器有限公司，上海)；酶标仪(BOX-998，Winooski，美国)。大花红景天素购自上海中药标准化研究中心，并经HPLC检测纯度均在98％以上。L-DOPA(100g，V900425)，曲酸(5g，K3125)均购自SIGMA公司，美国。
1.2样品配制同
2多巴为底物的分光光度法
目前常用的分光光度法多采用L-DOPA和酪氨酸酶为反应体系。操作方法就是最终体积3mL(包括1.5mM L-DOPA，0.1mM PBS pH＝6.5，酪氨酸酶12.4U/mL)。加入酶后触发反应，在30℃密闭水浴锅反应20min，最后移至96孔板中在475nm波长下检测[3]，实验结果见图3和表3。
酪氨酸酶抑制率计算使用以下公式：
表3用以多巴为底物的分光光度法检测大花红景天素抑制酪氨酸酶生成黑色素的抑制率
本发明所涉及的多个方面已做如上阐述。然而，应理解的是，在不偏离本发明精神之前提下，本领域专业人员可对其进行等同改变和修饰，所述改变和修饰同样落入本申请所附权利要求的覆盖范围。
Claims (2)
1.大花红景天素在制备抑制酪氨酸酶活性的药物或保健品或化妆品中的应用。
2.如权利要求1所述的应用，其特征在于，所述的大花红景天素是作为唯一的活性成分应用于抑制酪氨酸酶活性的药物或保健品或化妆品的制备中。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610458230.1A CN107519163B (zh) | 2016-06-22 | 2016-06-22 | 大花红景天素的医药用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610458230.1A CN107519163B (zh) | 2016-06-22 | 2016-06-22 | 大花红景天素的医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107519163A true CN107519163A (zh) | 2017-12-29 |
| CN107519163B CN107519163B (zh) | 2020-02-18 |
Family
ID=60735469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610458230.1A Expired - Fee Related CN107519163B (zh) | 2016-06-22 | 2016-06-22 | 大花红景天素的医药用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519163B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321600A (zh) * | 2020-10-26 | 2021-02-05 | 吉林大学 | 一种从大株红景天中提取分离大花红景天素的方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104257545A (zh) * | 2014-09-18 | 2015-01-07 | 北京工商大学 | 一种红景天发酵原浆化妆品及其制备方法 |
| WO2015160030A1 (ko) * | 2014-04-15 | 2015-10-22 | 한국콜마주식회사 | 피부 미백 활성을 갖는 마키아신 및 이의 용도 |
| CN105671125A (zh) * | 2014-11-20 | 2016-06-15 | 上海中医药大学 | 一种酪氨酸酶抑制剂或促进剂的筛选方法 |
-
2016
- 2016-06-22 CN CN201610458230.1A patent/CN107519163B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015160030A1 (ko) * | 2014-04-15 | 2015-10-22 | 한국콜마주식회사 | 피부 미백 활성을 갖는 마키아신 및 이의 용도 |
| CN104257545A (zh) * | 2014-09-18 | 2015-01-07 | 北京工商大学 | 一种红景天发酵原浆化妆品及其制备方法 |
| CN105671125A (zh) * | 2014-11-20 | 2016-06-15 | 上海中医药大学 | 一种酪氨酸酶抑制剂或促进剂的筛选方法 |
Non-Patent Citations (4)
| Title |
|---|
| HSIU-MEI CHIANG ET AL.: "Hydroalcoholic extract of Rhodiola rosea L. (Crassulaceae) and its hydrolysate inhibit melanogenesis in B16F0 cells by regulating the CREB/MITF/tyrosinase pathway", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
| JINGE ZHOU ET AL.: "Improved TLC Bioautographic Assay for Qualitative and Quantitative Estimation of Tyrosinase Inhibitors in Natural Products", 《PHYTOCHEM. ANAL.》 * |
| TONG ZHOU ET AL.: "Chemical Components and Bioactivities of Rhodiola rosea", 《INTERNATIONAL JOURNAL OF TRADITIONAL AND NATURAL MEDICINES》 * |
| 赵进等: "红景天活性成分的提取工艺及其美容功效研究", 《日用化学工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321600A (zh) * | 2020-10-26 | 2021-02-05 | 吉林大学 | 一种从大株红景天中提取分离大花红景天素的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107519163B (zh) | 2020-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100459970C (zh) | 具有协同增白作用的皮肤增白组合物 | |
| Song et al. | Comparison of the antimelanogenic effects of p-coumaric acid and its methyl ester and their skin permeabilities | |
| CN106977586A (zh) | 一种促进组织修复的美洲大蠊新多肽及应用 | |
| CN107519163A (zh) | 大花红景天素的医药用途 | |
| CN113893184A (zh) | 一种多肽美白祛斑组合物、及护肤品和制备方法 | |
| CN107260612B (zh) | 祛除黄褐斑组合物、应用、复合制剂及制备方法 | |
| CN107519190A (zh) | 4‑烯丙基苯‑1‑O‑β‑D‑葡萄糖苷的医药用途 | |
| CN102552309B (zh) | 一种透明质酸金的用途及其制备方法 | |
| CN101890031A (zh) | 一种治疗皮肤溃疡的外用药物组合物及其制备方法 | |
| KR101528448B1 (ko) | 살비아놀릭산 b를 포함하는 피부상태 개선용 조성물 | |
| KR100406124B1 (ko) | 자외선에 의해 증가하는 프로스타글란딘을 억제하는성분과 멜라닌 합성을 억제하는 성분을 동시에 함유하는미백 화장료 조성물 | |
| CA3086433C (en) | Use of cannabidiol or cannabis extract in preparation of skin whitening products | |
| CN103796631A (zh) | 含有羟基积雪草苷的皮肤美白组合物 | |
| KR102092227B1 (ko) | 비스 페닐 헥사 트리엔 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 피부 미백용 조성물 | |
| KR20120105623A (ko) | 마데카소사이드를 함유하는 피부 미백제 | |
| CN104940185B (zh) | 刺芒柄花素的医药用途 | |
| KR102527079B1 (ko) | 피부 미백용 조성물 | |
| CN109758379A (zh) | 一种复方凝血酸组合物及其制备方法、产品 | |
| CN100577623C (zh) | 脱色药 | |
| CN106727682A (zh) | 一种用于治疗脱发的制剂 | |
| CN103638055A (zh) | 拟黑多刺蚁提取物及其和抗真菌医药用途 | |
| CN109010094A (zh) | 一种白藜芦醇美容养颜化妆品及制备方法 | |
| KR20130082063A (ko) | 아테미신산, 이의 유도체 및 이의 약학적으로 허용 가능한 염을 함유하는 피부 미백제 | |
| KR100497151B1 (ko) | 신규한 펩타이드 화합물 및 그 용도 | |
| WO2024107037A1 (ko) | 엔테로코커스 페칼리스 열처리 사균체를 포함하는 항산화 및 미백용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200218 |